Research ExplorerPublicationsMesothelin Expression in Human Tumors: A Tissue Microarray S...

Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors

Standard

Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. / Weidemann, Sören; Gagelmann, Pauline; Gorbokon, Natalia; Lennartz, Maximilian; Menz, Anne; Luebke, Andreas M; Kluth, Martina; Hube-Magg, Claudia; Blessin, Niclas C; Fraune, Christoph; Möller, Katharina; Bernreuther, Christian; Lebok, Patrick; Clauditz, Till S; Jacobsen, Frank; Izbicki, Jakob R; Jansen, Kristina; Sauter, Guido; Uhlig, Ria; Wilczak, Waldemar; Steurer, Stefan; Minner, Sarah; Burandt, Eike; Krech, Rainer H; Dum, David; Krech, Till; Marx, Andreas H; Simon, Ronald.

In: BIOMEDICINES, Vol. 9, No. 4, 397, 07.04.2021.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Weidemann, S, Gagelmann, P, Gorbokon, N, Lennartz, M, Menz, A, Luebke, AM, Kluth, M, Hube-Magg, C, Blessin, NC, Fraune, C, Möller, K, Bernreuther, C, Lebok, P, Clauditz, TS, Jacobsen, F, Izbicki, JR, Jansen, K, Sauter, G, Uhlig, R, Wilczak, W, Steurer, S, Minner, S, Burandt, E, Krech, RH, Dum, D, Krech, T, Marx, AH & Simon, R 2021, 'Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors', BIOMEDICINES, vol. 9, no. 4, 397. https://doi.org/10.3390/biomedicines9040397

APA

Weidemann, S., Gagelmann, P., Gorbokon, N., Lennartz, M., Menz, A., Luebke, A. M., Kluth, M., Hube-Magg, C., Blessin, N. C., Fraune, C., Möller, K., Bernreuther, C., Lebok, P., Clauditz, T. S., Jacobsen, F., Izbicki, J. R., Jansen, K., Sauter, G., Uhlig, R., ... Simon, R. (2021). Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. BIOMEDICINES, 9(4), [397]. https://doi.org/10.3390/biomedicines9040397

Vancouver

Weidemann S, Gagelmann P, Gorbokon N, Lennartz M, Menz A, Luebke AM et al. Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. BIOMEDICINES. 2021 Apr 7;9(4). 397. https://doi.org/10.3390/biomedicines9040397

Bibtex

@article{38cf2f3a1a3d4d25984c7142955cc299,
title = "Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors",
abstract = "Mesothelin (MSLN) represents an attractive molecule for targeted cancer therapies. To identify tumors that might benefit from such therapies, tissue microarrays including 15,050 tumors from 122 different tumor types and 76 healthy organs were analyzed for MSLN expression by immunohistochemistry. Sixty-six (54%) tumor types showed at least occasional weak staining, including 50 (41%) tumor types with at least one strongly positive sample. Highest prevalence of MSLN positivity had ovarian carcinomas (serous 97%, clear cell 83%, endometrioid 77%, mucinous 71%, carcinosarcoma 65%), pancreatic adenocarcinoma (ductal 75%, ampullary 81%), endometrial carcinomas (clear cell 71%, serous 57%, carcinosarcoma 50%, endometrioid 45%), malignant mesothelioma (69%), and adenocarcinoma of the lung (55%). MSLN was rare in cancers of the breast (7% of 1138), kidney (7% of 807), thyroid gland (1% of 638), soft tissues (0.3% of 931), and prostate (0 of 481). High expression was linked to advanced pathological tumor (pT) stage (p < 0.0001) and metastasis (p < 0.0001) in 1619 colorectal adenocarcinomas, but unrelated to parameters of malignancy in 1072 breast-, 386 ovarian-, 174 lung-, 757 kidney-, 171 endometrial-, 373 gastric-, and 925 bladder carcinomas. In summary, numerous important cancer types with high-level MSLN expression might benefit from future anti-MSLN therapies, but MSLN's prognostic relevance appears to be limited.",
author = "S{\"o}ren Weidemann and Pauline Gagelmann and Natalia Gorbokon and Maximilian Lennartz and Anne Menz and Luebke, {Andreas M} and Martina Kluth and Claudia Hube-Magg and Blessin, {Niclas C} and Christoph Fraune and Katharina M{\"o}ller and Christian Bernreuther and Patrick Lebok and Clauditz, {Till S} and Frank Jacobsen and Izbicki, {Jakob R} and Kristina Jansen and Guido Sauter and Ria Uhlig and Waldemar Wilczak and Stefan Steurer and Sarah Minner and Eike Burandt and Krech, {Rainer H} and David Dum and Till Krech and Marx, {Andreas H} and Ronald Simon",
year = "2021",
month = apr,
day = "7",
doi = "10.3390/biomedicines9040397",
language = "English",
volume = "9",
journal = "BIOMEDICINES",
issn = "2227-9059",
publisher = "MDPI AG",
number = "4",

}

RIS

TY - JOUR

T1 - Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors

AU - Weidemann, Sören

AU - Gagelmann, Pauline

AU - Gorbokon, Natalia

AU - Lennartz, Maximilian

AU - Menz, Anne

AU - Luebke, Andreas M

AU - Kluth, Martina

AU - Hube-Magg, Claudia

AU - Blessin, Niclas C

AU - Fraune, Christoph

AU - Möller, Katharina

AU - Bernreuther, Christian

AU - Lebok, Patrick

AU - Clauditz, Till S

AU - Jacobsen, Frank

AU - Izbicki, Jakob R

AU - Jansen, Kristina

AU - Sauter, Guido

AU - Uhlig, Ria

AU - Wilczak, Waldemar

AU - Steurer, Stefan

AU - Minner, Sarah

AU - Burandt, Eike

AU - Krech, Rainer H

AU - Dum, David

AU - Krech, Till

AU - Marx, Andreas H

AU - Simon, Ronald

PY - 2021/4/7

Y1 - 2021/4/7

N2 - Mesothelin (MSLN) represents an attractive molecule for targeted cancer therapies. To identify tumors that might benefit from such therapies, tissue microarrays including 15,050 tumors from 122 different tumor types and 76 healthy organs were analyzed for MSLN expression by immunohistochemistry. Sixty-six (54%) tumor types showed at least occasional weak staining, including 50 (41%) tumor types with at least one strongly positive sample. Highest prevalence of MSLN positivity had ovarian carcinomas (serous 97%, clear cell 83%, endometrioid 77%, mucinous 71%, carcinosarcoma 65%), pancreatic adenocarcinoma (ductal 75%, ampullary 81%), endometrial carcinomas (clear cell 71%, serous 57%, carcinosarcoma 50%, endometrioid 45%), malignant mesothelioma (69%), and adenocarcinoma of the lung (55%). MSLN was rare in cancers of the breast (7% of 1138), kidney (7% of 807), thyroid gland (1% of 638), soft tissues (0.3% of 931), and prostate (0 of 481). High expression was linked to advanced pathological tumor (pT) stage (p < 0.0001) and metastasis (p < 0.0001) in 1619 colorectal adenocarcinomas, but unrelated to parameters of malignancy in 1072 breast-, 386 ovarian-, 174 lung-, 757 kidney-, 171 endometrial-, 373 gastric-, and 925 bladder carcinomas. In summary, numerous important cancer types with high-level MSLN expression might benefit from future anti-MSLN therapies, but MSLN's prognostic relevance appears to be limited.

AB - Mesothelin (MSLN) represents an attractive molecule for targeted cancer therapies. To identify tumors that might benefit from such therapies, tissue microarrays including 15,050 tumors from 122 different tumor types and 76 healthy organs were analyzed for MSLN expression by immunohistochemistry. Sixty-six (54%) tumor types showed at least occasional weak staining, including 50 (41%) tumor types with at least one strongly positive sample. Highest prevalence of MSLN positivity had ovarian carcinomas (serous 97%, clear cell 83%, endometrioid 77%, mucinous 71%, carcinosarcoma 65%), pancreatic adenocarcinoma (ductal 75%, ampullary 81%), endometrial carcinomas (clear cell 71%, serous 57%, carcinosarcoma 50%, endometrioid 45%), malignant mesothelioma (69%), and adenocarcinoma of the lung (55%). MSLN was rare in cancers of the breast (7% of 1138), kidney (7% of 807), thyroid gland (1% of 638), soft tissues (0.3% of 931), and prostate (0 of 481). High expression was linked to advanced pathological tumor (pT) stage (p < 0.0001) and metastasis (p < 0.0001) in 1619 colorectal adenocarcinomas, but unrelated to parameters of malignancy in 1072 breast-, 386 ovarian-, 174 lung-, 757 kidney-, 171 endometrial-, 373 gastric-, and 925 bladder carcinomas. In summary, numerous important cancer types with high-level MSLN expression might benefit from future anti-MSLN therapies, but MSLN's prognostic relevance appears to be limited.

U2 - 10.3390/biomedicines9040397

DO - 10.3390/biomedicines9040397

M3 - SCORING: Journal article

C2 - 33917081

VL - 9

JO - BIOMEDICINES

JF - BIOMEDICINES

SN - 2227-9059

IS - 4

M1 - 397

ER -